Literature DB >> 85182

Treatment of metastatic malignant melanoma with pimozide.

R N Taub, M A Baker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 85182     DOI： 10.1016/s0140-6736(79)91025-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  8 in total

1.  The STAT3 inhibitor pimozide impedes cell proliferation and induces ROS generation in human osteosarcoma by suppressing catalase expression.

Authors:  Nan Cai; Wei Zhou; Lan-Lan Ye; Jun Chen; Qiu-Ni Liang; Gang Chang; Jia-Jie Chen
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

2.  The neuroleptic drug pimozide inhibits stem-like cell maintenance and tumorigenicity in hepatocellular carcinoma.

Authors:  Jia-Jie Chen; Nan Cai; Guan-Zhong Chen; Chang-Chang Jia; Dong-Bo Qiu; Cong Du; Wei Liu; Yang Yang; Zi-Jie Long; Qi Zhang
Journal:  Oncotarget       Date:  2017-03-14

3.  PD-1-siRNA delivered by attenuated Salmonella enhances the antimelanoma effect of pimozide.

Authors:  Tiesuo Zhao; Tian Wei; Jing Guo; Yangeng Wang; Xiangyi Shi; Sheng Guo; Xiaolong Jia; Huijie Jia; Zhiwei Feng
Journal:  Cell Death Dis       Date:  2019-02-18       Impact factor: 8.469

4.  Pimozide Inhibits the Human Prostate Cancer Cells Through the Generation of Reactive Oxygen Species.

Authors:  Ukjin Kim; C-Yoon Kim; Ji Min Lee; Bokyeong Ryu; Jin Kim; Changsoo Shin; Jae-Hak Park
Journal:  Front Pharmacol       Date:  2020-01-16       Impact factor: 5.810

Review 5.  Targeting Reactive Oxygen Species Capacity of Tumor Cells with Repurposed Drug as an Anticancer Therapy.

Authors:  Jiabing Wang; Dongsheng Sun; Lili Huang; Shijian Wang; Yong Jin
Journal:  Oxid Med Cell Longev       Date:  2021-09-07       Impact factor: 6.543

Review 6.  Repurposing antipsychotics of the diphenylbutylpiperidine class for cancer therapy.

Authors:  Vikram Shaw; Suyash Srivastava; Sanjay K Srivastava
Journal:  Semin Cancer Biol       Date:  2019-10-13       Impact factor: 15.707

Review 7.  Drug rechanneling: A novel paradigm for cancer treatment.

Authors:  Itishree Kaushik; Sharavan Ramachandran; Sahdeo Prasad; Sanjay K Srivastava
Journal:  Semin Cancer Biol       Date:  2020-05-11       Impact factor: 15.707

8.  The enhanced antitumour response of pimozide combined with the IDO inhibitor L‑MT in melanoma.

Authors:  Huijie Jia; Wenjing Ren; Yuchen Feng; Tian Wei; Mengmeng Guo; Jing Guo; Jingjing Zhao; Xiangfeng Song; Mingyong Wang; Tiesuo Zhao; Hui Wang; Zhiwei Feng; Zhongwei Tian
Journal:  Int J Oncol       Date:  2018-07-06       Impact factor: 5.650
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.